Resminostat also disturbed the Akt signaling pathway by reducing 4E-BP1 and p70S6k phosphorylation.648 In addition, resminostat exerted an antitumor effect when combined with ruxolitinib in CTCL models.649 In the phase II SAPHIRE trial, resminostat showed an ORR of 34% in R/R HL patients.650 Abexinostat, also named PCI-24781, is a pan-HDAC inhibitor that mainly targets HDAC1. Here, HDAC1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.